Kit for in Vitro Diagnosis of Anthrax

The first enzyme-linked immunosorbent assay (ELISA) has been developed for in vitro diagnosis of anthrax. The kit has been cleared by the U.S. Food and Drug Administration (FDA) and has also received the CE mark.

The kit provides laboratories with a simple and rapid means to confirm anthrax infection in a potential bioterrorism incident or in cases of natural exposure. Called QuickELISA, the kit detects antibodies to the protective antigen of Bacillicus anthracis. In clinical trials, the test detected 100% of the patients with confirmed inhalational or cutaneous anthrax. The kit can also be used to monitor antibodies generated in response to vaccination against anthrax with protective antigen (PA)-based vaccines.

The kit includes a 96-well breakaway microplate, all reagents, and controls. The turnaround time for the assay is about 45 minutes from start to finish. The test detects antibodies of all isotypes in human as well as nonhuman species. The kit is the product of Immunetics, Inc. (Boston, MA, USA).




Related Links:
Immunetics